CN108368115B - 吡咯并嘧啶化合物的盐 - Google Patents
吡咯并嘧啶化合物的盐 Download PDFInfo
- Publication number
- CN108368115B CN108368115B CN201680072397.2A CN201680072397A CN108368115B CN 108368115 B CN108368115 B CN 108368115B CN 201680072397 A CN201680072397 A CN 201680072397A CN 108368115 B CN108368115 B CN 108368115B
- Authority
- CN
- China
- Prior art keywords
- compound
- formula
- hydrochloride
- hydrochloride salt
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Abstract
Description
Claims (10)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2015109327865 | 2015-12-15 | ||
CN201510932786 | 2015-12-15 | ||
PCT/CN2016/109835 WO2017101777A1 (zh) | 2015-12-15 | 2016-12-14 | 吡咯并嘧啶化合物的盐 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108368115A CN108368115A (zh) | 2018-08-03 |
CN108368115B true CN108368115B (zh) | 2020-01-03 |
Family
ID=59055858
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201680072397.2A Active CN108368115B (zh) | 2015-12-15 | 2016-12-14 | 吡咯并嘧啶化合物的盐 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN108368115B (zh) |
WO (1) | WO2017101777A1 (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2019413421A1 (en) | 2018-12-24 | 2021-08-12 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Treatment use of pyrrolopyrimidine compound, and solid pharmaceutical composition of pyrrolopyrimidine compound |
CN114981272A (zh) * | 2020-03-09 | 2022-08-30 | 正大天晴药业集团股份有限公司 | 吡咯并嘧啶化合物的治疗噬血细胞综合征的用途 |
CN117500807A (zh) * | 2021-06-21 | 2024-02-02 | 正大天晴药业集团股份有限公司 | 吡咯并嘧啶化合物及其药物组合物治疗慢性移植物抗宿主病的用途 |
WO2023179547A1 (zh) * | 2022-03-21 | 2023-09-28 | 正大天晴药业集团股份有限公司 | 吡咯并嘧啶化合物治疗中高危骨髓纤维化的用途 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105777754A (zh) * | 2014-12-16 | 2016-07-20 | 北京赛林泰医药技术有限公司 | 吡咯并嘧啶化合物 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2700433T3 (es) * | 2005-12-13 | 2019-02-15 | Incyte Holdings Corp | Derivados de pirrolo[2,3-d]pirimidina como inhibidores de quinasas Janus |
-
2016
- 2016-12-14 CN CN201680072397.2A patent/CN108368115B/zh active Active
- 2016-12-14 WO PCT/CN2016/109835 patent/WO2017101777A1/zh active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105777754A (zh) * | 2014-12-16 | 2016-07-20 | 北京赛林泰医药技术有限公司 | 吡咯并嘧啶化合物 |
Also Published As
Publication number | Publication date |
---|---|
WO2017101777A1 (zh) | 2017-06-22 |
CN108368115A (zh) | 2018-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11007197B2 (en) | EGFR modulators and uses thereof | |
EP2880035B9 (en) | Novel pyrrolopyrimidine compounds as inhibitors of protein kinases | |
EP2694485B1 (en) | Combination of akt inhibitor compound and vemurafenib for use in therapeutic treatments | |
CN108368115B (zh) | 吡咯并嘧啶化合物的盐 | |
CN112010839B (zh) | 靶向丝/苏氨酸激酶抑制剂的晶型 | |
WO2019154091A1 (zh) | 取代的二氨基嘧啶化合物 | |
EP4319754A1 (en) | Combination therapies using prmt5 inhibitors for the treatment of cancer | |
US20220194946A1 (en) | Fgfr inhibitors and methods of making and using the same | |
US11654145B2 (en) | Combination therapy involving diaryl macrocyclic compounds | |
US10414767B2 (en) | Deuterated quinazolinone compound and pharmaceutical composition comprising same | |
CN104230912B (zh) | 喹啉衍生物、其制备方法及其用途 | |
JP2022522395A (ja) | 選択的エストロゲン受容体分解剤の新規な塩 | |
KR20230038523A (ko) | Wee1 억제제의 염 및 형태 | |
CN111100117B (zh) | 氨基嘧啶类化合物甲磺酸盐的晶型a及其制备方法和应用 | |
CN116768856A (zh) | 一种取代的氨基六元氮杂环类化合物的盐及其晶型、制备方法和应用 | |
CN103635183A (zh) | 使用pi3k/mtor的吡啶并嘧啶抑制剂来治疗淋巴瘤的方法 | |
US9018242B2 (en) | Salt form of tyrosine kinase inhibitor | |
WO2019228330A1 (zh) | 取代的苯并[d]咪唑类化合物及其药物组合物 | |
WO2023091746A1 (en) | Combination therapy comprising an fgfr inhibitor and a kras inhibitor | |
CN108137614B (zh) | 一种稠合嘧啶化合物及包含该化合物的组合物及其用途 | |
CN113966330A (zh) | PLK4抑制剂(1R,2S)-(E)-2-(3-(4-((顺式-2,6-二甲基吗啉)甲基)苯乙烯基)-1H-咪唑-6-基)-5’-甲氧基螺[环丙烷-l,3’-吲哚啉]-2’-酮富马酸盐的晶型S4 | |
TWI814468B (zh) | 藥用組合物、其製備方法及用途 | |
CN108299419B (zh) | 一种新型egfr激酶抑制剂的几种新晶型及其制备方法 | |
CN115716850A (zh) | 芳基磷氧化合物的晶型、制备方法及用途 | |
CN117466898A (zh) | 氨基吡唑并嘧啶化合物的晶体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20190530 Address after: No. 369, Yuzhou South Road, Lianyungang, Jiangsu Province Applicant after: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Applicant after: Capital Pharmaceutical Holdings (Beijing) Co., Ltd. Applicant after: Lianyungang Runzhong Pharmaceutical Co.,Ltd. Address before: 222062 Yuzhou South Road, Haizhou District, Lianyungang, Jiangsu 369 Applicant before: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Applicant before: Beijing Centaurus Biopharma Technology Co., Ltd. Applicant before: Lianyungang Runzhong Pharmaceutical Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: No. 369, Yuzhou South Road, Lianyungang, Jiangsu Province Patentee after: CHIA TAI TIANQING PHARMACEUTICAL GROUP Co.,Ltd. Patentee after: Capital Pharmaceutical Holdings (Beijing) Co.,Ltd. Patentee after: LIANYUNGANG RUNZHONG PHARMACEUTICAL Co.,Ltd. Address before: No. 369, Yuzhou South Road, Lianyungang, Jiangsu Province Patentee before: CHIA TAI TIANQING PHARMACEUTICAL GROUP Co.,Ltd. Patentee before: Shouyao holding (Beijing) Co.,Ltd. Patentee before: LIANYUNGANG RUNZHONG PHARMACEUTICAL Co.,Ltd. |